MedTrace Logo

A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer

NCT01874678 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2016-01-12

No results posted yet for this study

Summary

Objectives:

1. Primary Objective:

To bridge the data of efficacy in term of overall response rate of TS-1 plus cisplatin in Taiwanese advanced NSCLC patients from that gained from Japanese population
2. Secondary Objectives:

A. To assess progression free survival B. To assess overall survival C. To bridge the safety profile by assessing the toxicities and tolerability

Conditions

  • Non-small-cell Lung Cancer (NSCLC)

Interventions

DRUG

TS-1/Cisplatin

Sponsors & Collaborators

  • TTY Biopharm

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01874678 on ClinicalTrials.gov